CA3242396A1 - Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide - Google Patents

Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Info

Publication number
CA3242396A1
CA3242396A1 CA3242396A CA3242396A CA3242396A1 CA 3242396 A1 CA3242396 A1 CA 3242396A1 CA 3242396 A CA3242396 A CA 3242396A CA 3242396 A CA3242396 A CA 3242396A CA 3242396 A1 CA3242396 A1 CA 3242396A1
Authority
CA
Canada
Prior art keywords
oea
formulation
steatosis
liver
oleoylethanolamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242396A
Other languages
English (en)
French (fr)
Inventor
Daniele Piomelli
Lin Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3242396A1 publication Critical patent/CA3242396A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3242396A 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide Pending CA3242396A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265314P 2021-12-13 2021-12-13
US63/265,314 2021-12-13
PCT/US2022/081372 WO2023114722A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Publications (1)

Publication Number Publication Date
CA3242396A1 true CA3242396A1 (en) 2023-06-22

Family

ID=86773562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242396A Pending CA3242396A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Country Status (8)

Country Link
US (1) US20250041249A1 (https=)
EP (1) EP4447950A1 (https=)
JP (1) JP2025500841A (https=)
KR (1) KR20240134319A (https=)
CN (1) CN118900687A (https=)
AU (1) AU2022416432A1 (https=)
CA (1) CA3242396A1 (https=)
WO (1) WO2023114722A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573920A1 (en) * 2023-12-22 2025-06-25 Centre National de la Recherche Scientifique Texturizing complex comprising oleoylethanolamide and at least one fatty substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579413A (zh) * 2011-01-14 2012-07-18 傅瑾 油酰乙醇胺及其衍生物的新用途
US12383502B2 (en) * 2017-04-13 2025-08-12 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US10702487B2 (en) * 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity

Also Published As

Publication number Publication date
WO2023114722A1 (en) 2023-06-22
AU2022416432A1 (en) 2024-07-25
KR20240134319A (ko) 2024-09-09
EP4447950A1 (en) 2024-10-23
CN118900687A (zh) 2024-11-05
US20250041249A1 (en) 2025-02-06
JP2025500841A (ja) 2025-01-15

Similar Documents

Publication Publication Date Title
AU2018211328A1 (en) Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
WO2009046865A3 (en) Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent
GB2397016B (en) Intranasal analgesic composition containing buprenorphine
US20250195439A1 (en) Method for treating local lesion disease
WO2009039980A3 (en) Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
JP6430109B2 (ja) 外用組成物
WO2009033668A3 (en) Use of a peptide as a therapeutic agent
WO2009040068A3 (en) Use of a peptide as a therapeutic agent
WO2009040045A3 (en) Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
WO2009033767A3 (en) Use of a peptide as a therapeutic agent
WO2009033718A3 (en) Use of anti -inflammatory peptide 1 as a therapeutic agent
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
WO2009033780A3 (en) Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
WO2012092527A1 (en) Delivery of treatments transdermally for fungal infections and other indications
WO2009033791A3 (en) Use of a peptide as a therapeutic agent
CA3242396A1 (en) Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
CN1942163A (zh) 生发剂
PL1684719T3 (pl) Kompozycje alfa 1-antytrypsyny i sposoby leczenia z zastosowaniem takich kompozycji
WO2009040070A3 (en) Use of helodermin as a therapeutic agent
MX2023005303A (es) Inhibidor de raf para el tratamiento del glioma de bajo grado.
WO2009043469A3 (en) Use of pneumadin as a therapeutic agent
AU2013202114B2 (en) Acne treatment
MXPA05013901A (es) Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma.
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
JP2019043898A (ja) 皮膚常在菌叢改善剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206